APO Research
Talk to an analyst

APO RESEARCH · REPORT

Quadrivalent Flu Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Quadrivalent Flu Vaccine Market Analysis and Forecast 2026-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchQuadrivalent Flu Vaccine Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Quadrivalent Flu Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Quadrivalent Flu Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Quadrivalent Flu Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Quadrivalent Flu Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Quadrivalent Flu Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Quadrivalent Flu Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Quadrivalent Flu Vaccine include CSL, Sanofi Pasteur, AstraZeneca, GlaxoSmithKline and Abbott, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Quadrivalent Flu Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Quadrivalent Flu Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Quadrivalent Flu Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Quadrivalent Flu Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Quadrivalent Flu Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Quadrivalent Flu Vaccine sales, projected growth trends, production technology, application and end-user industry.

Quadrivalent Flu Vaccine Segment by Company

CSL

Sanofi Pasteur

AstraZeneca

GlaxoSmithKline

Abbott

Quadrivalent Flu Vaccine Segment by Type

Intramuscular Injection

Nasal Spray

Intradermal Shot

Quadrivalent Flu Vaccine Segment by Application

Clinic

Hospital

Public Health Agency

Other

Quadrivalent Flu Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quadrivalent Flu Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Quadrivalent Flu Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quadrivalent Flu Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Quadrivalent Flu Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Quadrivalent Flu Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Quadrivalent Flu Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Intramuscular Injection Major Manufacturers Table 3. Nasal Spray Major Manufacturers Table 4. Intradermal Shot Major Manufacturers Table 5. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Clinic Major Manufacturers Table 7. Hospital Major Manufacturers Table 8. Public Health Agency Major Manufacturers Table 9. Other Major Manufacturers Table 10. Quadrivalent Flu Vaccine Industry Trends Table 11. Quadrivalent Flu Vaccine Industry Drivers Table 12. Quadrivalent Flu Vaccine Industry Opportunities and Challenges Table 13. Quadrivalent Flu Vaccine Industry Restraints Table 14. Global Quadrivalent Flu Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Quadrivalent Flu Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Quadrivalent Flu Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2021-2026) Table 18. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2027-2032) Table 19. Global Quadrivalent Flu Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k doses) Table 20. Global Quadrivalent Flu Vaccine Sales by Region (2021-2026) & (k doses) Table 21. Global Quadrivalent Flu Vaccine Sales by Region (2027-2032) & (k doses) Table 22. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2021-2026) Table 23. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2027-2032) Table 24. Global Quadrivalent Flu Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Quadrivalent Flu Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Quadrivalent Flu Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Quadrivalent Flu Vaccine Sales Market Share by Manufacturers (2021-2026) Table 28. Global Quadrivalent Flu Vaccine Sales Price (US$/dose) of Manufacturers (2021-2026) Table 29. Global Quadrivalent Flu Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Quadrivalent Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Quadrivalent Flu Vaccine Manufacturers, Product Type & Application Table 32. Global Quadrivalent Flu Vaccine Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Quadrivalent Flu Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Quadrivalent Flu Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2026) Table 39. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2027-2032) Table 40. Global Quadrivalent Flu Vaccine Sales by Type 2021 VS 2025 VS 2032 (k doses) Table 41. Global Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 42. Global Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 43. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2026) Table 44. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2027-2032) Table 45. Global Quadrivalent Flu Vaccine Price by Type (2021-2026) & (US$/dose) Table 46. Global Quadrivalent Flu Vaccine Price by Type (2027-2032) & (US$/dose) Table 47. Global Quadrivalent Flu Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2026) Table 51. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2027-2032) Table 52. Global Quadrivalent Flu Vaccine Sales by Application 2021 VS 2025 VS 2032 (k doses) Table 53. Global Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 54. Global Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 55. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2026) Table 56. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2027-2032) Table 57. Global Quadrivalent Flu Vaccine Price by Application (2021-2026) & (US$/dose) Table 58. Global Quadrivalent Flu Vaccine Price by Application (2027-2032) & (US$/dose) Table 59. CSL Company Information Table 60. CSL Business Overview Table 61. CSL Quadrivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 62. CSL Quadrivalent Flu Vaccine Product Portfolio Table 63. CSL Recent Development Table 64. Sanofi Pasteur Company Information Table 65. Sanofi Pasteur Business Overview Table 66. Sanofi Pasteur Quadrivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 67. Sanofi Pasteur Quadrivalent Flu Vaccine Product Portfolio Table 68. Sanofi Pasteur Recent Development Table 69. AstraZeneca Company Information Table 70. AstraZeneca Business Overview Table 71. AstraZeneca Quadrivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 72. AstraZeneca Quadrivalent Flu Vaccine Product Portfolio Table 73. AstraZeneca Recent Development Table 74. GlaxoSmithKline Company Information Table 75. GlaxoSmithKline Business Overview Table 76. GlaxoSmithKline Quadrivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Quadrivalent Flu Vaccine Product Portfolio Table 78. GlaxoSmithKline Recent Development Table 79. Abbott Company Information Table 80. Abbott Business Overview Table 81. Abbott Quadrivalent Flu Vaccine Sales (k doses), Revenue (US$ Million), Price (US$/dose) and Gross Margin (2021-2026) Table 82. Abbott Quadrivalent Flu Vaccine Product Portfolio Table 83. Abbott Recent Development Table 84. North America Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 87. North America Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 88. North America Quadrivalent Flu Vaccine Sales Price by Type (2021-2026) & (US$/dose) Table 89. North America Quadrivalent Flu Vaccine Sales Price by Type (2027-2032) & (US$/dose) Table 90. North America Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 93. North America Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 94. North America Quadrivalent Flu Vaccine Sales Price by Application (2021-2026) & (US$/dose) Table 95. North America Quadrivalent Flu Vaccine Sales Price by Application (2027-2032) & (US$/dose) Table 96. North America Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 98. North America Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 99. North America Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 100. North America Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 101. North America Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 102. North America Quadrivalent Flu Vaccine Sales Price by Country (2021-2026) & (US$/dose) Table 103. North America Quadrivalent Flu Vaccine Sales Price by Country (2027-2032) & (US$/dose) Table 104. United States Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 105. Canada Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 106. Mexico Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 107. Europe Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 110. Europe Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 111. Europe Quadrivalent Flu Vaccine Sales Price by Type (2021-2026) & (US$/dose) Table 112. Europe Quadrivalent Flu Vaccine Sales Price by Type (2027-2032) & (US$/dose) Table 113. Europe Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 116. Europe Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 117. Europe Quadrivalent Flu Vaccine Sales Price by Application (2021-2026) & (US$/dose) Table 118. Europe Quadrivalent Flu Vaccine Sales Price by Application (2027-2032) & (US$/dose) Table 119. Europe Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. Europe Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. Europe Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 123. Europe Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 124. Europe Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 125. Europe Quadrivalent Flu Vaccine Sales Price by Country (2021-2026) & (US$/dose) Table 126. Europe Quadrivalent Flu Vaccine Sales Price by Country (2027-2032) & (US$/dose) Table 127. Germany Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 128. France Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 129. U.K. Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 130. Italy Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 131. Russia Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 132. Spain Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 133. Netherlands Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 134. Switzerland Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 135. Sweden Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 136. Poland Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 137. China Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 138. China Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 139. China Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 140. China Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 141. China Quadrivalent Flu Vaccine Sales Price by Type (2021-2026) & (US$/dose) Table 142. China Quadrivalent Flu Vaccine Sales Price by Type (2027-2032) & (US$/dose) Table 143. China Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 144. China Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 145. China Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 146. China Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 147. China Quadrivalent Flu Vaccine Sales Price by Application (2021-2026) & (US$/dose) Table 148. China Quadrivalent Flu Vaccine Sales Price by Application (2027-2032) & (US$/dose) Table 149. Asia Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 152. Asia Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 153. Asia Quadrivalent Flu Vaccine Sales Price by Type (2021-2026) & (US$/dose) Table 154. Asia Quadrivalent Flu Vaccine Sales Price by Type (2027-2032) & (US$/dose) Table 155. Asia Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 158. Asia Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 159. Asia Quadrivalent Flu Vaccine Sales Price by Application (2021-2026) & (US$/dose) Table 160. Asia Quadrivalent Flu Vaccine Sales Price by Application (2027-2032) & (US$/dose) Table 161. Asia Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Asia Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Asia Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 165. Asia Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 166. Asia Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 167. Asia Quadrivalent Flu Vaccine Sales Price by Country (2021-2026) & (US$/dose) Table 168. Asia Quadrivalent Flu Vaccine Sales Price by Country (2027-2032) & (US$/dose) Table 169. Japan Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 170. South Korea Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 171. India Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 172. Australia Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 173. Taiwan Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 174. Southeast Asia Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 175. SAMEA Quadrivalent Flu Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 176. SAMEA Quadrivalent Flu Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 177. SAMEA Quadrivalent Flu Vaccine Sales by Type (2021-2026) & (k doses) Table 178. SAMEA Quadrivalent Flu Vaccine Sales by Type (2027-2032) & (k doses) Table 179. SAMEA Quadrivalent Flu Vaccine Sales Price by Type (2021-2026) & (US$/dose) Table 180. SAMEA Quadrivalent Flu Vaccine Sales Price by Type (2027-2032) & (US$/dose) Table 181. SAMEA Quadrivalent Flu Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 182. SAMEA Quadrivalent Flu Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 183. SAMEA Quadrivalent Flu Vaccine Sales by Application (2021-2026) & (k doses) Table 184. SAMEA Quadrivalent Flu Vaccine Sales by Application (2027-2032) & (k doses) Table 185. SAMEA Quadrivalent Flu Vaccine Sales Price by Application (2021-2026) & (US$/dose) Table 186. SAMEA Quadrivalent Flu Vaccine Sales Price by Application (2027-2032) & (US$/dose) Table 187. SAMEA Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. SAMEA Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. SAMEA Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. SAMEA Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k doses) Table 191. SAMEA Quadrivalent Flu Vaccine Sales by Country (2021-2026) & (k doses) Table 192. SAMEA Quadrivalent Flu Vaccine Sales by Country (2027-2032) & (k doses) Table 193. SAMEA Quadrivalent Flu Vaccine Sales Price by Country (2021-2026) & (US$/dose) Table 194. SAMEA Quadrivalent Flu Vaccine Sales Price by Country (2027-2032) & (US$/dose) Table 195. Brazil Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 196. Argentina Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 197. Chile Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Colombia Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 199. Peru Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 200. Saudi Arabia Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 201. Israel Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 202. UAE Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 203. Turkey Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 204. Iran Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 205. Egypt Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Quadrivalent Flu Vaccine Distributors List Table 209. Quadrivalent Flu Vaccine Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Quadrivalent Flu Vaccine Image Figure 2. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Quadrivalent Flu Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Intramuscular Injection Image Figure 5. Nasal Spray Image Figure 6. Intradermal Shot Image Figure 7. Global Quadrivalent Flu Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Quadrivalent Flu Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Clinic Image Figure 10. Hospital Image Figure 11. Public Health Agency Image Figure 12. Other Image Figure 13. Global Quadrivalent Flu Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Quadrivalent Flu Vaccine Revenue (2021-2032) & (US$ Million) Figure 15. Global Quadrivalent Flu Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Quadrivalent Flu Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2021-2032) Figure 18. Global Quadrivalent Flu Vaccine Sales (2021-2032) & (k doses) Figure 19. Global Quadrivalent Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k doses) Figure 20. Global Quadrivalent Flu Vaccine Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Quadrivalent Flu Vaccine Sales YoY (2021-2032) & (k doses) Figure 22. Europe Quadrivalent Flu Vaccine Sales YoY (2021-2032) & (k doses) Figure 23. China Quadrivalent Flu Vaccine Sales YoY (2021-2032) & (k doses) Figure 24. Asia (Excluding China) Quadrivalent Flu Vaccine Sales YoY (2021-2032) & (k doses) Figure 25. South America, Middle East and Africa Quadrivalent Flu Vaccine Sales YoY (2021-2032) & (k doses) Figure 26. Global Quadrivalent Flu Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Quadrivalent Flu Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Quadrivalent Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Quadrivalent Flu Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2032) Figure 32. Global Quadrivalent Flu Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k doses) Figure 33. Global Quadrivalent Flu Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2032) Figure 35. Global Quadrivalent Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Quadrivalent Flu Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2032) Figure 38. Global Quadrivalent Flu Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k doses) Figure 39. Global Quadrivalent Flu Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2032) Figure 41. North America Quadrivalent Flu Vaccine Revenue Share by Type (2021-2032) Figure 42. North America Quadrivalent Flu Vaccine Sales Share by Type (2021-2032) Figure 43. North America Quadrivalent Flu Vaccine Revenue Share by Application (2021-2032) Figure 44. North America Quadrivalent Flu Vaccine Sales Share by Application (2021-2032) Figure 45. North America Quadrivalent Flu Vaccine Revenue Share by Country (2021-2032) Figure 46. North America Quadrivalent Flu Vaccine Sales Share by Country (2021-2032) Figure 47. Europe Quadrivalent Flu Vaccine Revenue Share by Type (2021-2032) Figure 48. Europe Quadrivalent Flu Vaccine Sales Share by Type (2021-2032) Figure 49. Europe Quadrivalent Flu Vaccine Revenue Share by Application (2021-2032) Figure 50. Europe Quadrivalent Flu Vaccine Sales Share by Application (2021-2032) Figure 51. Europe Quadrivalent Flu Vaccine Revenue Share by Country (2021-2032) Figure 52. Europe Quadrivalent Flu Vaccine Sales Share by Country (2021-2032) Figure 53. China Quadrivalent Flu Vaccine Revenue Share by Type (2021-2032) Figure 54. China Quadrivalent Flu Vaccine Sales Share by Type (2021-2032) Figure 55. China Quadrivalent Flu Vaccine Revenue Share by Application (2021-2032) Figure 56. China Quadrivalent Flu Vaccine Sales Share by Application (2021-2032) Figure 57. Asia Quadrivalent Flu Vaccine Revenue Share by Type (2021-2032) Figure 58. Asia Quadrivalent Flu Vaccine Sales Share by Type (2021-2032) Figure 59. Asia Quadrivalent Flu Vaccine Revenue Share by Application (2021-2032) Figure 60. Asia Quadrivalent Flu Vaccine Sales Share by Application (2021-2032) Figure 61. Asia Quadrivalent Flu Vaccine Revenue Share by Country (2021-2032) Figure 62. Asia Quadrivalent Flu Vaccine Sales Share by Country (2021-2032) Figure 63. SAMEA Quadrivalent Flu Vaccine Revenue Share by Type (2021-2032) Figure 64. SAMEA Quadrivalent Flu Vaccine Sales Share by Type (2021-2032) Figure 65. SAMEA Quadrivalent Flu Vaccine Revenue Share by Application (2021-2032) Figure 66. SAMEA Quadrivalent Flu Vaccine Sales Share by Application (2021-2032) Figure 67. SAMEA Quadrivalent Flu Vaccine Revenue Share by Country (2021-2032) Figure 68. SAMEA Quadrivalent Flu Vaccine Sales Share by Country (2021-2032) Figure 69. Quadrivalent Flu Vaccine Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Quadrivalent Flu Vaccine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Intramuscular Injection
  • Nasal Spray
  • Intradermal Shot
Applications
  • Clinic
  • Hospital
  • Public Health Agency
  • Other
Companies covered
  • CSL
  • Sanofi Pasteur
  • AstraZeneca
  • GlaxoSmithKline
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Quadrivalent Flu Vaccine Market by Type
  3. 1.2.1 Global Quadrivalent Flu Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Intramuscular Injection
  5. 1.2.3 Nasal Spray
  6. 1.2.4 Intradermal Shot
  7. 1.3 Quadrivalent Flu Vaccine Market by Application
  8. 1.3.1 Global Quadrivalent Flu Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinic
  10. 1.3.3 Hospital
  11. 1.3.4 Public Health Agency
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Quadrivalent Flu Vaccine Market Dynamics
  1. 2.1 Quadrivalent Flu Vaccine Industry Trends
  2. 2.2 Quadrivalent Flu Vaccine Industry Drivers
  3. 2.3 Quadrivalent Flu Vaccine Industry Opportunities and Challenges
  4. 2.4 Quadrivalent Flu Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Quadrivalent Flu Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Quadrivalent Flu Vaccine Revenue by Region
  3. 3.2.1 Global Quadrivalent Flu Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Quadrivalent Flu Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Quadrivalent Flu Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Quadrivalent Flu Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Quadrivalent Flu Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Quadrivalent Flu Vaccine Sales by Region
  9. 3.4.1 Global Quadrivalent Flu Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Quadrivalent Flu Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Quadrivalent Flu Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Quadrivalent Flu Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Quadrivalent Flu Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Quadrivalent Flu Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Quadrivalent Flu Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Quadrivalent Flu Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Quadrivalent Flu Vaccine Sales by Manufacturers
  6. 4.2.1 Global Quadrivalent Flu Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Quadrivalent Flu Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Quadrivalent Flu Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Quadrivalent Flu Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Quadrivalent Flu Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Quadrivalent Flu Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Quadrivalent Flu Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Quadrivalent Flu Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Quadrivalent Flu Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Quadrivalent Flu Vaccine Tier 1, Tier 2, and Tier 3
5 Quadrivalent Flu Vaccine Market by Type
  1. 5.1 Global Quadrivalent Flu Vaccine Revenue by Type
  2. 5.1.1 Global Quadrivalent Flu Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Quadrivalent Flu Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Quadrivalent Flu Vaccine Sales by Type
  6. 5.2.1 Global Quadrivalent Flu Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Quadrivalent Flu Vaccine Sales by Type (2021-2032) & (k doses)
  8. 5.2.3 Global Quadrivalent Flu Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Quadrivalent Flu Vaccine Price by Type
6 Quadrivalent Flu Vaccine Market by Application
  1. 6.1 Global Quadrivalent Flu Vaccine Revenue by Application
  2. 6.1.1 Global Quadrivalent Flu Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Quadrivalent Flu Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Quadrivalent Flu Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Quadrivalent Flu Vaccine Sales by Application
  6. 6.2.1 Global Quadrivalent Flu Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Quadrivalent Flu Vaccine Sales by Application (2021-2032) & (k doses)
  8. 6.2.3 Global Quadrivalent Flu Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Quadrivalent Flu Vaccine Price by Application
7 Company Profiles
  1. 7.1 CSL
  2. 7.1.1 CSL Company Information
  3. 7.1.2 CSL Business Overview
  4. 7.1.3 CSL Quadrivalent Flu Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 CSL Quadrivalent Flu Vaccine Product Portfolio
  6. 7.1.5 CSL Recent Developments
  7. 7.2 Sanofi Pasteur
  8. 7.2.1 Sanofi Pasteur Company Information
  9. 7.2.2 Sanofi Pasteur Business Overview
  10. 7.2.3 Sanofi Pasteur Quadrivalent Flu Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Pasteur Quadrivalent Flu Vaccine Product Portfolio
  12. 7.2.5 Sanofi Pasteur Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Quadrivalent Flu Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Quadrivalent Flu Vaccine Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Quadrivalent Flu Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Quadrivalent Flu Vaccine Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 Abbott
  26. 7.5.1 Abbott Company Information
  27. 7.5.2 Abbott Business Overview
  28. 7.5.3 Abbott Quadrivalent Flu Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Abbott Quadrivalent Flu Vaccine Product Portfolio
  30. 7.5.5 Abbott Recent Developments
8 North America
  1. 8.1 North America Quadrivalent Flu Vaccine Market Size by Type
  2. 8.1.1 North America Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Quadrivalent Flu Vaccine Price by Type (2021-2032)
  5. 8.2 North America Quadrivalent Flu Vaccine Market Size by Application
  6. 8.2.1 North America Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Quadrivalent Flu Vaccine Price by Application (2021-2032)
  9. 8.3 North America Quadrivalent Flu Vaccine Market Size by Country
  10. 8.3.1 North America Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Quadrivalent Flu Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Quadrivalent Flu Vaccine Market Size by Type
  2. 9.1.1 Europe Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Quadrivalent Flu Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Quadrivalent Flu Vaccine Market Size by Application
  6. 9.2.1 Europe Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Quadrivalent Flu Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Quadrivalent Flu Vaccine Market Size by Country
  10. 9.3.1 Europe Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Quadrivalent Flu Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Quadrivalent Flu Vaccine Market Size by Type
  2. 10.1.1 China Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Quadrivalent Flu Vaccine Price by Type (2021-2032)
  5. 10.2 China Quadrivalent Flu Vaccine Market Size by Application
  6. 10.2.1 China Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Quadrivalent Flu Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Quadrivalent Flu Vaccine Market Size by Type
  2. 11.1.1 Asia Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Quadrivalent Flu Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Quadrivalent Flu Vaccine Market Size by Application
  6. 11.2.1 Asia Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Quadrivalent Flu Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Quadrivalent Flu Vaccine Market Size by Country
  10. 11.3.1 Asia Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Quadrivalent Flu Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Quadrivalent Flu Vaccine Market Size by Type
  2. 12.1.1 SAMEA Quadrivalent Flu Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Quadrivalent Flu Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Quadrivalent Flu Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Quadrivalent Flu Vaccine Market Size by Application
  6. 12.2.1 SAMEA Quadrivalent Flu Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Quadrivalent Flu Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Quadrivalent Flu Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Quadrivalent Flu Vaccine Market Size by Country
  10. 12.3.1 SAMEA Quadrivalent Flu Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Quadrivalent Flu Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Quadrivalent Flu Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Quadrivalent Flu Vaccine Value Chain Analysis
  2. 13.1.1 Quadrivalent Flu Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Quadrivalent Flu Vaccine Production Mode & Process
  6. 13.2 Quadrivalent Flu Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Quadrivalent Flu Vaccine Distributors
  9. 13.2.3 Quadrivalent Flu Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst